These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 36865164)
1. Three-Dimensional Bioconjugated Liquid-Like Solid (LLS) Enhance Characterization of Solid Tumor - Chimeric Antigen Receptor T cell interactions. Nguyen DT; Liu R; Ogando-Rivas E; Pepe A; Pedro D; Qdasait S; Nguyen NTY; Lavrador JM; Golde GR; Smolchek RA; Ligon J; Jin L; Tao H; Webber A; Phillpot S; Mitchell DA; Sayour EJ; Huang J; Castillo P; Sawyer WG bioRxiv; 2023 Feb; ():. PubMed ID: 36865164 [TBL] [Abstract][Full Text] [Related]
2. Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions. Nguyen DT; Liu R; Ogando-Rivas E; Pepe A; Pedro D; Qdaisat S; Nguyen NTY; Lavrador JM; Golde GR; Smolchek RA; Ligon J; Jin L; Tao H; Webber A; Phillpot S; Mitchell DA; Sayour EJ; Huang J; Castillo P; Gregory Sawyer W Acta Biomater; 2023 Dec; 172():466-479. PubMed ID: 37788737 [TBL] [Abstract][Full Text] [Related]
3. Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma. Zhu G; Zhang J; Zhang Q; Jin G; Su X; Liu S; Liu F Cancer Immunol Immunother; 2022 Oct; 71(10):2433-2448. PubMed ID: 35249119 [TBL] [Abstract][Full Text] [Related]
4. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors. Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008 [No Abstract] [Full Text] [Related]
5. CAR T Cell Locomotion in Solid Tumor Microenvironment. Nguyen DT; Ogando-Rivas E; Liu R; Wang T; Rubin J; Jin L; Tao H; Sawyer WW; Mendez-Gomez HR; Cascio M; Mitchell DA; Huang J; Sawyer WG; Sayour EJ; Castillo P Cells; 2022 Jun; 11(12):. PubMed ID: 35741103 [TBL] [Abstract][Full Text] [Related]
6. Gene modification strategies for next-generation CAR T cells against solid cancers. Tian Y; Li Y; Shao Y; Zhang Y J Hematol Oncol; 2020 May; 13(1):54. PubMed ID: 32423475 [TBL] [Abstract][Full Text] [Related]
7. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy. Das S; Valton J; Duchateau P; Poirot L Front Immunol; 2023; 14():1172681. PubMed ID: 37251405 [TBL] [Abstract][Full Text] [Related]
8. Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor. Myers Chen K; Grun D; Gautier B; Venkatesha S; Maddox M; Zhang AH; Andersen P Front Immunol; 2024; 15():1380065. PubMed ID: 38726005 [TBL] [Abstract][Full Text] [Related]
10. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290 [TBL] [Abstract][Full Text] [Related]
11. Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells. Zhang PF; Wang C; Zhang L; Li Q Immunotherapy; 2022 Apr; 14(6):459-473. PubMed ID: 35232284 [TBL] [Abstract][Full Text] [Related]
12. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo. Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000 [TBL] [Abstract][Full Text] [Related]
13. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234 [TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cell suppresses the efficacy of CAR-T toward killing lymphoma cells by modulating the microenvironment through stanniocalcin-1. Zhang R; Liu Q; Zhou S; He H; Zhao M; Ma W Elife; 2023 Feb; 12():. PubMed ID: 36779699 [TBL] [Abstract][Full Text] [Related]
15. Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma. Liang T; Song Y; Gu L; Wang Y; Ma W Int J Gen Med; 2023; 16():4121-4141. PubMed ID: 37720174 [TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment and CAR-T cell immunotherapy in B-cell lymphoma. Cai F; Zhang J; Gao H; Shen H Eur J Haematol; 2024 Feb; 112(2):223-235. PubMed ID: 37706523 [TBL] [Abstract][Full Text] [Related]
17. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. Dagar G; Gupta A; Masoodi T; Nisar S; Merhi M; Hashem S; Chauhan R; Dagar M; Mirza S; Bagga P; Kumar R; Akil ASA; Macha MA; Haris M; Uddin S; Singh M; Bhat AA J Transl Med; 2023 Jul; 21(1):449. PubMed ID: 37420216 [TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptors for the Tumour Microenvironment. Habib R; Nagrial A; Micklethwaite K; Gowrishankar K Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326 [TBL] [Abstract][Full Text] [Related]
19. JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment. Khanali J; Azangou-Khyavy M; Boroomand-Saboor M; Ghasemi M; Niknejad H Front Immunol; 2021; 12():638639. PubMed ID: 34177890 [TBL] [Abstract][Full Text] [Related]
20. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies. Antonucci L; Canciani G; Mastronuzzi A; Carai A; Del Baldo G; Del Bufalo F Front Immunol; 2022; 13():867154. PubMed ID: 35603195 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]